Guggenheim reissued their buy rating on shares of Dianthus Therapeutics (NASDAQ:DNTH - Free Report) in a research note released on Wednesday morning,Benzinga reports. Guggenheim currently has a $84.00 target price on the stock.
A number of other research firms also recently weighed in on DNTH. Raymond James upgraded Dianthus Therapeutics to a "moderate buy" rating in a research report on Thursday, December 12th. HC Wainwright reiterated a "buy" rating and issued a $40.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday. Finally, TD Cowen began coverage on shares of Dianthus Therapeutics in a research report on Friday, December 20th. They set a "buy" rating for the company. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $52.14.
Get Our Latest Research Report on Dianthus Therapeutics
Dianthus Therapeutics Stock Performance
DNTH traded down $0.62 on Wednesday, reaching $21.28. The company had a trading volume of 259,714 shares, compared to its average volume of 226,840. Dianthus Therapeutics has a 52-week low of $18.13 and a 52-week high of $33.77. The company has a market cap of $629.82 million, a price-to-earnings ratio of -8.51 and a beta of 1.82. The business has a 50 day simple moving average of $22.65 and a 200 day simple moving average of $24.94.
Dianthus Therapeutics (NASDAQ:DNTH - Get Free Report) last announced its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The company had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. As a group, equities research analysts predict that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.
Hedge Funds Weigh In On Dianthus Therapeutics
Hedge funds have recently made changes to their positions in the business. MetLife Investment Management LLC boosted its holdings in Dianthus Therapeutics by 3.1% in the fourth quarter. MetLife Investment Management LLC now owns 14,372 shares of the company's stock valued at $313,000 after acquiring an additional 433 shares in the last quarter. Invesco Ltd. raised its stake in Dianthus Therapeutics by 7.4% in the fourth quarter. Invesco Ltd. now owns 11,521 shares of the company's stock worth $251,000 after buying an additional 790 shares in the last quarter. SG Americas Securities LLC lifted its holdings in Dianthus Therapeutics by 9.2% in the fourth quarter. SG Americas Securities LLC now owns 9,653 shares of the company's stock worth $210,000 after buying an additional 814 shares during the period. Barclays PLC grew its holdings in shares of Dianthus Therapeutics by 2.6% during the 4th quarter. Barclays PLC now owns 42,766 shares of the company's stock worth $933,000 after acquiring an additional 1,082 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Dianthus Therapeutics by 0.7% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company's stock worth $3,641,000 after acquiring an additional 1,092 shares in the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.
About Dianthus Therapeutics
(
Get Free Report)
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Featured Stories

Before you consider Dianthus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dianthus Therapeutics wasn't on the list.
While Dianthus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.